Thrombopoietin: Its role from early hematopoiesis to platelet production

Haematologica

Volumn 84, Issue 2, 1999, Pages 158-166

  Wendling, Françoise ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Hematopoiesis; Megakaryopoiesis; Mpl ligand; Stem cells; Thrombopoietin

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; FLT3 LIGAND; GROWTH FACTOR; INTERLEUKIN 3; NEUTRALIZING ANTIBODY; PACLITAXEL; RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; THROMBOCYTOPOIESIS;

ANIMALS; HEMATOPOIESIS; HUMANS; PLATELET COUNT; THROMBOPOIETIN;

EID: 0032832532     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (138)

1. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythemic sera. Acta Haematol (Basel) 1958; 20: 350-5.
2. Gordon MS, Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment ofthrombocytopenia. Blood 1992; 80:302-7.
3. Burstein SA. Platelets and cytokines. Curr Opin Hematol 1994; 1:373-80.
4. Vainchenker W, Debili N, Mouthon MA, Wendling F. Megakaryocytopoiesis: Cellular aspects and regulation. Crit Rev Oncol/Hematol 1995; 20:165-92.
5. Wendling F, Han Z-C. Positive and negative regulation of megakaryocytopoiesis. Ballière's Clin Haematol 1997; 10:29-45.
6. Wendling F, Varlet P, Charon M, Tambourin P. MPLV: a retrovirus complex inducing an acute myeloproliferative disorder in mice. Virology 1986; 149:242-6.
7. Souyri M, Vigon I, Penciolelli J-F, Heard J-M, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137-47.
8. Bazan JF. Haematopoietic receptors and helical cytokines. Immunol Today 1990; 11:350-4.
9. Vigon I, Mornon J-P, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89:5640-4.
10. Vigon I, Florindo C, Fichelson S, et al. Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth. Oncogene 1993; 8:2607-15.
11. Skoda RC, Seldin DC, Chiang M-K, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J 1993; 12:2645-53.
12. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395-401.
13. Debili N, Wendling F, Cosman D, et al.The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85:391-401.
14. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265:1445-7.
15. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that its a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117-24.
16. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994; 369:533-8.
17. Lok S, Foster DC. The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cells 1994; 12:586-98.
18. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994; 353:57-61.
19. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994; 84:1464-72.
20. Wendling F, Maraskovsky E, Debili N, et al. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369:571-4.
21. Hokom MM, Lancey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486-92.
22. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511-21.
23. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin and stimulation of platelet production in vivo. Nature 1994; 369:564-8.
24. Gurney AL, Kuang W-J, Xie M-H, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85:981-8.
25. Huffman RC, Andersen H, Walker K, et al. Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from Ser1 to Arg246. Biochemistry 1996; 35:14849-61.
26. Eaton DL, de Sauvage FJ. Thrombopoietin: The primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997; 25:1-7.
27. Chang M-S, McNinch J, Basu R, et al. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Bioch Chem 1995; 270:511-4.
28. Foster D, Lok S. Biological roles for the second domain of thrombopoietin. Stem Cells 1996; 14:102-7.
29. Drachman JG, Kaushansky K. Structure and function of the cytokine receptor superfamily. Curr Opin Hematol 1995; 2:22-8.
30. Park H, Park SS, Jin EH, et al. Identification of functionally important residues of human thrombopoietin. J Biol Chem 1998; 273:256-61.
31. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696-9.
32. Dower WJ, Cwirla SE, Balasubramanian P, Schatz PJ, Baccanari D, Barrett RW. Peptide agonists of the thrombopoietin receptor. Stem Cells 1998; 16(suppl 2):21-9.
33. Suzukawa K, Satoh H, Taniwaki M, Yokota J, Morishita K. The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome). Leukemia 1995; 9:1328-31.
34. Schnittger S, de Sauvage FJ, Le Paslier D, Fonatsch C. Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26. Leukemia 1996; 10:1891-6.
35. Foster DC, Sprecher CA, Kramer JM, et al. Human thrombopoietin: gene structure, cDNA sequence, expression and chromosomal localization. Proc Natl Acad Sci USA 1994; 91:13023-7.
36. Kamura T, Handa H, Hamasaki N, Kitajima S. Characterization of the human thrombopoietin gene promoter. J Biol Chem 1997; 272:11361-8.
37. Bouscary D, Fontenay-Roupie M, Chretien S, et al. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995; 91:425-7.
38. Nomura S, Ogami K, Tsukamoto I, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Haemat 1997; 25:565-72.
39. Cardier JE, Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: Evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood 1998; 91:923-9.
40. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1996; 89:101-7.
41. Shimada Y, Kato T, Ogami K, et al. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23:1388-96.
42. McDonald TP, Wendling F, Vainchenker W, Mc Carty JM, Jorgensen MJ, Kaushansky K. Thrombopoietin from human embryonic kidney cells is the same factor as c-mpl-Ligand. Blood 1995; 85:292-4.
43. Guerriero A, Worford L, Holland HK, Guo G-R, Sheedan K, Waller EK. Thrombopoietin is synthesized by bone marrow stromal cells. Blood 1997; 90:3444-55.
44. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85:2720-30.
45. Bondurant MC, Koury M. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 1986; 6:2731-9.
46. de Gabriele G, Pennington DG. Regulation of platelet production. Br J Haematol 1967; 13:210-7.
47. Stoffer R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87:567-73.
48. Cohen-Solal K, Villeval J-L, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcript during thrombocytopenia and thrombocytosis. Blood 1996; 88:2578-84.
49. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokaro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997; 77:808-14.
50. Chang M-S, Hsu R-Y, McNinch J, Copeland NG, Jenkins NA. The gene for murine megakaryocyte growth and development factor (Thrombopoietin, Thpo) is located on mouse chromosome 16. Genomics 1995; 26:636-7.
51. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87:2154-61.
52. de Sauvage FJ, Carver-Moore K, Luoh S-M, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183:651-6.
53. McCarthy JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-75.
54. Hirayama Y, Sakamaki T, Matsunaga T, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 1998; 92:46-52.
55. Broudy V, Lin N, Sabath D, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89:1896-904.
56. Kuwaki T, Hagiwara T, Yuki C, Kodama I, Kato T, Miyazaki H. Quantitative analysis of thrombopoietin receptors on human megakaryocytes. FEBS Lett 1998; 427:46-50.
57. Sato T, Fuse A, Niimi H, Fielder PJ, Avraham H. Binding and regulation of thrombopoietin to human megakaryocytes. Br J Haematol 1998; 100:704-11.
58. Fielder P, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89:2782-8.
59. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of actions of thrombopoietin/ MGDF in megakaryocyte development. Cell 1995; 81:695-704.
60. Shivdasani RA, Fielder P, Keller G-A, Orkin SH, de Sauvage FJ. Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice. Blood 1997; 90:1821-7.
61. Tahara T, Usuki K, Sato H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haematopoietic disorders. Br J Haematol 1996; 93:783-8.
62. Folman CC, von dem Borne AE, Rensink IH, et al. Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay. Thromb Haemostas 1997; 78:1262-7.
63. Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068-71.
64. Mukai HY, Kojima H, Todokoro K, et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996; 76:675-8.
65. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol 1996; 95:535-41.
66. Marsh JCW, Gibson FM, Prue RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996; 95:605-10.
67. Kosugi S, Kutara Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93:704-6.
68. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenia purpura. Thromb Haemost 1996; 76:156-60.
69. Porcelijn L, Folman CC, Bossers B, et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998; 79:1101-5.
70. Depper JM, Leonard WJ, Drogula C, Kronke M, Waldmann TA, Greene WC. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci USA 1985; 82:4230-5.
71. Steinman RA, Tweardy DJ. Granulocyte colony-stimulating factor receptor mRNA upregulation is an immediate early marker of myeloid differentiation and exibits dysfunctional regulation in leukemic cells. Blood 1994; 83:119-27.
72. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand, thrombopoietin. Nature 1994; 369:568-71.
73. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86:419-31.
74. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92:3234-8.
75. Zeigler FC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84:4045-52.
76. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402-13.
77. Choi ES, Hokom M, Bartley T. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem cells 1995; 13:317-22.
78. Debili N, Wendling F, Katz A, et al. The Mpl-Ligand or thrombopoietin or megakaryocyte growth and development factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86:2516-25.
79. Choi E. Regulation of proplatelet and platelet formation in vitro. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, eds. Thrombopoiesis and thrombopoietins. Totowa, N J Humana Press, 1996. p. 271-84.
80. Zucker-Franklin D, Kaushansky K. Effects of thrombopoietin on the development of megakaryocytes and platelets. Blood 1996; 88:1632-40.
81. Choi ES, Hokom MM, Chen J-L, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996; 95:227-33.
82. Cramer E, Norol F, Guichard J, et al. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood 1997; 89:2326-46.
83. Norol F, Vitrat N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood 1998; 91:830-4.
84. Ito T, Ishida Y, Kuriya S-I. Recombinant human c-mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. Br J Haematol 1996; 94:387-90.
85. Bunting S, Widmer R, Lipari T, et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997; 90:3423-9.
86. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus Kinase 2 and Shc in human blood platelets. Blood 1995; 86:23-7.
87. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996; 87:439-46.
88. Miyakawa Y, Oda A, Drucker B, et al. Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. Blood 1997; 89:2789-98.
89. Oda A, Miyakawa Y, Druker BJ, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87:4664-70.
90. Chen J, Herced-Harjacek L, Groopman JE, Grabarek J. Regulation of platelets activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86:4054-62.
91. Toombs CF, Young CH, Glaspy JA, Varnum BC. Recombinant human megakaryocyte growth and development factor (MGDF) moderately enhances ex vivo platelet aggregation by a receptor dependent mechanism. Thromb Res 1995; 80:23-33.
92. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87:2762-8.
93. Alexander WS, Roberts AW, Nicola NA, Ll R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-mpl. Blood 1996; 87:2162-70.
94. Carver-Moore K, Broxmeyer HE, Luoh S-M, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996; 88: 803-8.
95. Solar GP, Kerr WG, Ziegler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4-10.
96. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1-3.
97. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with Steel Factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996; 87:4544-51.
98. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996; 87:4998-5005.
99. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996; 88:429-36.
100. Petzer AL, Zanstra PW, Piret JM, Eaves CJ. Differential cytokine effects on primitive (CD34+ CD38-) human hematopoietic cells: novel response to flt-3 ligand and thrombopoietin. J Exp Med 1996; 183:2551-7.
101. Ramsfjell V, Borge OJ, Veiby OP, et al. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: Distinct interactions with the ligands for c-kit and FLT3. Blood 1996; 88:4481-92.
102. Ohmizono Y, Sakabe H, Kimura T, et al. Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia 1997; 11:524-30.
103. Piacibello W, Sanavio SF, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89:2644-53.
104. Ramsfjell V, Borge OJ, Cui L, Jacobsen SEW. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells. J Immunol 1997; 158:5169-74.
105. Borge OJ, Ramsfjell V, Cui L, Jacobsen SEW. Ability of early acting cytokine to directly promote survival and suppress apoptosis of human primitive CD34+ CD38-bone marrow cells with multilineage potential at the single cell level: Key role of thrombopoietin. Blood 1997; 90:2282-9.
106. Alexander WS, Begley CG. Thrombopoietin in vitro and in vivo. Cytokines Cell Mol Ther 1998; 4:25-34.
107. Alexander WS. Cytokines in hematopoiesis. Int Rev Immunol 1998; 16:651-82.
108. Miyazaki H. Update on thrombopoietin in preclinical and clinical trials. Curr Opin Hematol 1998; 5:197-202.
109. Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size and ploidy. Blood 1997; 89:1683-7.
110. Daw NC, Arnold JT, Abushullaih BA, et al. A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. Blood 1998; 91:466-74.
111. Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86:971-6.
112. Thomas GR, Thibodeaux H, Erret CJ, et al. In vivo biological effects of various forms of thrombopoietin in a murine model of transient thrombocytopenia. Stem Cells 1996; 14:244-51.
113. Fibbe WE, Heemskerk DPM, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308-13.
114. Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996; 88:1509-14.
115. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996; 88:366-76.
116. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86:54-9.
117. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97:2145-51.
118. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonnuman primates. Blood 1996; 87:1833-44.
119. Harker LA, Marzec UM, Kelly AB, et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997; 89:155-65.
120. Kaushansky K, Broudy VC, Grossmann A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96:1683-7.
121. Grossmann A, Lenox J, Deisher TA, et al. Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996; 88:3363-70.
122. Begley CG. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand). Thromb Haemostas 1997; 78:42-6.
123. Basser RL, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHUMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-81.
124. O'Malley CJ, Rasko RL, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vitro activation. Blood 1996; 88:3288-98.
125. Vadjan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126: 673-81.
126. Rasko JE, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 1997; 97:871-88.
127. Fanucchi M, Glapsy J, Crawfold J, et al. Safety and biological effects of pegylated megakaryocyte growth and development factor in lung cancer patients receiving carboplatin and paclitaxel: Randomised, placebo-controlled phase I study. Proc Am Soc Clin Oncol 1996; 15:720-6.
128. Fanucchi MG, Glapsy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404-9.
129. Archimbaud E, Ottmann O, Lui Yin JA, et al. A randomised, double-blind, placebo-controlled study using PEG-rhuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): early results. Blood 1996; 88 (Suppl 1):447.
130. Vadhan-Raj S, Patel S, Broxmeyer HE, et al. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Blood 1996; 88(suppl 1):448.
131. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryoctyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118-28.
132. Li J, Xia Y, Kuter DJ. Analysis of the thrombopoietin receptor (Mpl) on platelets from normal and essential thrombocythemic (ET) patients. Blood 1996; 88:545-52.
133. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031-8.
134. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338:572-80.
135. Wiestner A, Schlemper RJ, van der Maas APC, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genetics 1998; 18:49-52.
136. Taksin A-L, Cohen-Solal K, Le Couedic J-P, et al. Myelofibrosis: Experimental models and human studies. Stem Cells 1998; 16 (suppl 2):155-64.
137. Taksin A-L, Le Couedic J-P, Massé A, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93:125-39.
138. Dai CH, Krantz SB, Sawyer ST. Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: A possible defect of phosphatase activity in polycythemia vera. Blood 1997; 89:3574-81.